{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.8","upperLimit":"7.2","value":"4.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"}],"units":"Participants"}],"description":"Progression Free Surival is defined as time in months from start of study treatment to first documentation of objective tumor progression as assessed by RECIST v1.1; Will be summarized using the method of Kaplan and Meier and Cox proportional hazards models.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients received 7 mg of MEDI0457 intramuscularly (weeks 1, 3, 7, 12, and every 8 weeks thereafter) and durvalumab 1500 mg intravenously every 4 weeks starting at week 4.","id":"OG000","title":"Treatment Group"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Up to 2 years","title":"Median Progression Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"Months"}